Advances in Cancer Immunology and Immunotherapy for Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) is a hematological malignancy characterized by the rapid, uncontrolled growth of immature myeloid cells, leading to bone marrow failure and poor prognosis, particularly in elderly patients. While chemotherapy and stem cell transplantation remain the standard treatments, AML's high relapse rates and drug resistance underscore the need for more effective therapies. Immunotherapy has emerged as a promising strategy, but its success in AML is limited by the tumor’s complex immune evasion mechanisms.

This Research Topic focuses on advancing the understanding of AML through the lens of cancer immunology, with particular emphasis on identifying novel immune-based treatment strategies. We aim to explore how the immune system interacts with AML, uncover the mechanisms by which AML evades immune surveillance, and evaluate immunotherapeutic approaches that may enhance treatment efficacy. We also seek to address challenges related to immune resistance and tumor heterogeneity.

The goal is to identify new immune-related therapeutic targets and explore potential immune-based treatments, such as immune checkpoint inhibitors, CAR-T cell therapies, and monoclonal antibodies, to improve patient outcomes in AML. We welcome submissions of original research, short articles, reviews, mini-reviews, and perspective articles focused on the following:

--Investigating immune-based mechanisms involved in AML progression and immune evasion.
--Exploring novel immunotherapeutic strategies, including immune checkpoint inhibitors, CAR-T cell therapies, and immune modulators, in both pre-clinical and clinical AML.
--Understanding how AML modulates the tumor microenvironment to suppress immune responses and developing strategies to overcome these mechanisms.
--Identifying immune biomarkers for AML diagnosis, prognosis, and treatment response.
--Conducting a comprehensive review of recent advancements in cancer immunology and immunotherapy specifically related to AML.


Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.